TARGETED THERAPY USING INTRADERMAL INJECTION OF ETANERCEPT FOR REMISSION INDUCTION IN DISCOID LUPUS ERYTHEMATOSUS (TARGET-DLE): RESULTS FROM A PROOF-OF-CONCEPT PHASE II TRIAL

被引：0
|
作者：
Yuzaiful, Md [1 ]
Yusof, Md [1 ]
Wittmann, Miriam [1 ]
Fernandez, Catherine [2 ]
Wilson, Duncan [2 ]
Edward, Sara [3 ]
Abignano, Giuseppina [1 ]
Alase, Adewonuola [1 ]
Sharples, Linda [4 ]
Laws, Philip [5 ]
Goodfield, Mark [5 ]
Vital, Edward M. [1 ]
Emery, Paul [1 ]
机构：
[1] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[2] Univ Leeds, Leeds Inst Clin Trials Res, Leeds, W Yorkshire, England
[3] Leeds Teaching Hosp NHS Trust, Dept Histopathol, Leeds, W Yorkshire, England
[4] London Sch Hyg & Trop Med, Dept Med Stat, London, England
[5] Leeds Teaching Hosp NHS Trust, Dept Dermatol, Leeds, W Yorkshire, England
来源：
RHEUMATOLOGY | 2019年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
244
引用
收藏
页数：2
相关论文
共 11 条
  • [1] A single-arm, phase II open-label trial to investigate the efficacy and safety of intradermal injection of etanercept for remission induction in discoid lupus erythematosus (TARGET-DLE)
    Yusof, M. Y. M.
    Wittmann, M.
    Fernandez, C.
    Wilson, D.
    Edward, S.
    Abignano, G.
    Alase, A.
    Sharples, L.
    Laws, P.
    Goodfield, M.
    Vital, E. M.
    Emery, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (06) : E191 - E192
  • [2] Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial
    Le Tourneau, C.
    Paoletti, X.
    Servant, N.
    Bieche, I.
    Gentien, D.
    Frio, T. Rio
    Vincent-Salomon, A.
    Servois, V.
    Romejon, J.
    Mariani, O.
    Bernard, V.
    Huppe, P.
    Pierron, G.
    Mulot, F.
    Callens, C.
    Wong, J.
    Mauborgne, C.
    Rouleau, E.
    Reyes, C.
    Henry, E.
    Leroy, Q.
    Gestraud, P.
    La Rosa, P.
    Escalup, L.
    Mitry, E.
    Tredan, O.
    Delord, J-P
    Campone, M.
    Goncalves, A.
    Isambert, N.
    Gavoille, C.
    Kamal, M.
    BRITISH JOURNAL OF CANCER, 2014, 111 (01) : 17 - 24
  • [3] Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial
    C Le Tourneau
    X Paoletti
    N Servant
    I Bièche
    D Gentien
    T Rio Frio
    A Vincent-Salomon
    V Servois
    J Romejon
    O Mariani
    V Bernard
    P Huppe
    G Pierron
    F Mulot
    C Callens
    J Wong
    C Mauborgne
    E Rouleau
    C Reyes
    E Henry
    Q Leroy
    P Gestraud
    P La Rosa
    L Escalup
    E Mitry
    O Trédan
    J-P Delord
    M Campone
    A Goncalves
    N Isambert
    C Gavoille
    M Kamal
    British Journal of Cancer, 2014, 111 : 17 - 24
  • [4] Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: Results from a randomized proof-of-concept phase II trial (IMbrave151).
    El-Khoueiry, Anthony B.
    Ren, Zhenggang
    Chon, Hong Jae
    Park, Joon Oh
    Kim, Jin Won
    Pressiani, Tiziana
    Li, Daneng
    Zhukova, Lyudmila
    Zhu, Andrew X.
    Chen, Ming-Huang
    Hack, Stephen Paul
    Wu, Stephanie
    Liu, Bo
    Guan, Xiangnan
    Lu, Shan
    Wang, Yulei
    Macarulla, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 435 - 435
  • [5] ALLOGENEIC UMBILICAL-CORD DERIVED MESENCHYMAL STROMAL CELLS MSC(UC) AS TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): SAFETY AND EARLY CLINICAL/BIOLOGICAL RESULTS FROM A PHASE I -II PROOF-OF-CONCEPT CLINICAL STUDY
    Farge, D.
    Biard, L.
    Weil, B.
    Loisel, S.
    Lansiaux, P.
    Munia, I.
    Girault, V.
    Charles, C.
    Korganow, A.
    Beuvon, C.
    Pugnet, G.
    Cacciatore, C.
    Abisror, N.
    Taupin, J.
    Cras, A.
    Lowdell, M.
    Tarte, K.
    CYTOTHERAPY, 2024, 26 (06) : S45 - S46
  • [6] IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study
    Kimball, Alexa B.
    Loesche, Christian
    Prens, Errol P.
    Bechara, Falk G.
    Weisman, Jamie
    Rozenberg, Izabela
    Jarvis, Philip
    Peters, Thomas
    Roth, Lukas
    Wieczorek, Grazyna
    Kolbinger, Frank
    Jemec, Gregor B. E.
    EXPERIMENTAL DERMATOLOGY, 2022, 31 (10) : 1522 - 1532
  • [7] Telehealth group Cognitive-Behavioral Therapy for Insomnia (CBT-I) in primary brain tumor: Primary outcomes from a single-arm phase II feasibility and proof-of-concept trial
    Loughan, Ashlee R.
    Lanoye, Autumn
    Willis, Kelcie D.
    Fox, Amber
    Ravyts, Scott G.
    Zukas, Alicia
    Kim, Youngdeok
    NEURO-ONCOLOGY, 2024, 26 (03) : 516 - 527
  • [8] Consistent efficacy responses of abrocitinib monotherapy across randomized controlled phase II/III clinical trials: results from JADE MONO-1, JADE MONO-2 and the phase IIb proof-of-concept trial
    Simpson, E. L.
    Gooderham, M. J.
    Thyssen, J. P.
    Chan, G.
    Tatulych, S.
    Biswas, P.
    Ofori, S.
    Thorpe, A.
    Rojo, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E76 - E76
  • [9] CONVENTIONAL REMISSION INDUCTION FOLLOWED BY INTENSIVE CONSOLIDATION WITHOUT MAINTENANCE THERAPY IN ADULT ACUTE LYMPHOBLASTIC-LEUKEMIA - RESULTS FROM A PHASE-II CLINICAL-TRIAL IN 130 PATIENTS
    DEKKER, AW
    VANTVEER, MB
    HAAK, HL
    VANDERLELIE, J
    OSSENKOPPELE, G
    SCHOUTEN, HC
    SONNEVELD, P
    VANPUTTEN, WLJ
    WILLEMZE, R
    LOWENBERG, B
    BLOOD, 1994, 84 (10) : A144 - A144
  • [10] MAGE-A3 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT THERAPY IN RESECTED STAGE IB/II NON-SMALL CELL LUNG CANCER (NSCLC): FROM PROOF-OF-CONCEPT TO PHASE III TRIAL (MAGRIT)
    Passlick, B.
    Vansteenkiste, J.
    Zielinski, M.
    Linder, A.
    Dahabreh, J.
    Esteban, E.
    Malinowski, W.
    Jassem, J.
    Lopez-Brea, M.
    Debruyne, C.
    LUNG CANCER, 2009, 64 : S45 - S45
12